Drug Profile


Alternative Names: CI 979; Mirameline; PD 129409; RU 35926; Vivad

Latest Information Update: 18 Sep 2000

Price : $50

At a glance

  • Originator Aventis
  • Class Nootropics
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 18 Sep 2000 Discontinued-III for Alzheimer's disease in European Union (PO)
  • 18 Sep 2000 Discontinued-III for Alzheimer's disease in USA (PO)
  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top